ZA200900070B - Hydroxylated and methoxylated cyclopenta [D] pyrimidines as AKT protein kinase inhibitors - Google Patents

Hydroxylated and methoxylated cyclopenta [D] pyrimidines as AKT protein kinase inhibitors

Info

Publication number: ZA200900070B
Authority: ZA; South Africa
Prior art keywords: pyrimidines; hydroxylated; protein kinase; kinase inhibitors; akt protein
Prior art date: 2006-07-06

Application number

ZA200900070A

Other languages

English (en)

Inventor

Ian S Mitchell

James F Blake

Rui Xu

Nicholas C Kallan

Dengming Xiao

Keith Lee Spencer

Josef R Bencsik

Jun Liang

Brian Safina

Birong Zhang

Christine Chabot

Steven Do

Eli M Wallace

Anna L Banka

Stephen T Schlachter

Original Assignee

Array Biopharma Inc

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-07-06

Filing date

2009-01-05

Publication date

2010-03-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38686743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200900070(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-01-05 Application filed by Array Biopharma Inc, Genentech Inc filed Critical Array Biopharma Inc

2010-03-31 Publication of ZA200900070B publication Critical patent/ZA200900070B/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Oncology (AREA)
Neurosurgery (AREA)
Virology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)

ZA200900070A 2006-07-06 2009-01-05 Hydroxylated and methoxylated cyclopenta [D] pyrimidines as AKT protein kinase inhibitors ZA200900070B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US81871806P	2006-07-06	2006-07-06

Publications (1)

Publication Number	Publication Date
ZA200900070B true ZA200900070B (en)	2010-03-31

Family

ID=38686743

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200900070A ZA200900070B (en)	2006-07-06	2009-01-05	Hydroxylated and methoxylated cyclopenta [D] pyrimidines as AKT protein kinase inhibitors

Country Status (34)

Country	Link
EP (4)	EP2402325B1 (fr)
JP (4)	JP5266216B2 (fr)
KR (5)	KR20150051240A (fr)
CN (2)	CN102816124A (fr)
AR (3)	AR061842A1 (fr)
AT (1)	ATE524447T1 (fr)
AU (1)	AU2007269060B2 (fr)
BR (3)	BR122013028012B8 (fr)
CA (2)	CA2656622C (fr)
CL (1)	CL2007001993A1 (fr)
CO (1)	CO6150161A2 (fr)
CR (1)	CR10600A (fr)
CY (1)	CY1112117T1 (fr)
DK (2)	DK2049501T3 (fr)
ES (3)	ES2372774T3 (fr)
HR (1)	HRP20110908T1 (fr)
HU (1)	HUE026237T2 (fr)
IL (2)	IL196028A (fr)
IN (1)	IN2014KN02886A (fr)
MA (1)	MA31655B1 (fr)
MX (4)	MX2008016202A (fr)
MY (1)	MY147364A (fr)
NO (1)	NO342346B1 (fr)
NZ (3)	NZ610633A (fr)
PL (2)	PL2402325T3 (fr)
PT (1)	PT2049501E (fr)
RS (1)	RS52212B (fr)
RU (2)	RU2478632C2 (fr)
SG (4)	SG188905A1 (fr)
SI (2)	SI2402325T1 (fr)
TW (2)	TW201332994A (fr)
UA (1)	UA95641C2 (fr)
WO (1)	WO2008006040A1 (fr)
ZA (1)	ZA200900070B (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA95641C2 (xx) *	2006-07-06	2011-08-25	Эррей Биофарма Инк.	Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
NZ573979A (en)	2006-07-06	2012-02-24	Array Biopharma Inc	Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
US8063050B2 (en) *	2006-07-06	2011-11-22	Array Biopharma Inc.	Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8329701B2 (en)	2006-07-06	2012-12-11	Array Biopharma Inc.	Dihydrofuro pyrimidines as AKT protein kinase inhibitors
ATE532789T1 (de) *	2006-07-06	2011-11-15	Array Biopharma Inc	Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
US20110135569A1 (en)	2007-03-20	2011-06-09	Peak Biosciences Inc.	Method for therapeutic administration of radionucleosides
ES2551352T3 (es)	2007-07-05	2015-11-18	Array Biopharma, Inc.	Pirimido ciclopentanos útiles para el tratamiento de enfermedades inflamatorias o hiperproliferativas
MX2009014013A (es)	2007-07-05	2010-01-28	Array Biopharma Inc	Pirimidil ciclopentanos como inhibidores de la proteina cinasa akt.
US8846683B2 (en)	2007-07-05	2014-09-30	Array Biopharma, Inc.	Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
US9409886B2 (en)	2007-07-05	2016-08-09	Array Biopharma Inc.	Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
ES2426092T3 (es)	2008-01-09	2013-10-21	Array Biopharma, Inc.	5H-Ciclopenta[d]pirimidinas como inhibidores de proteínas cinasas AKT
EP2240483B8 (fr)	2008-01-09	2013-04-03	Array Biopharma, Inc.	Pyrimidyl cyclopentanes en tant qu'inhibiteurs de protéine kinase akt
EP2240455B1 (fr) *	2008-01-09	2012-12-26	Array Biopharma, Inc.	Pyrimidyl cyclopentane hydroxylé en tant qu'inhibiteur de protéine kinase akt
ES2422733T3 (es)	2008-01-09	2013-09-13	Array Biopharma Inc	Pirimidilciclopentanos hidroxilados como inhibidores de proteínas cinasas AKT
EP2655619A4 (fr) *	2010-12-23	2014-10-22	Genentech Inc	Polythérapie combinant un inducteur et un inhibiteur d'autophagie pour le traitement de néoplasmes
SG10201504303SA (en) *	2011-04-01	2015-07-30	Genentech Inc	Combinations Of AKT Inhibitor Compounds And Chemotherapeutic Agents, And Methods Of Use
SG10201507582VA (en) *	2011-04-01	2015-10-29	Genentech Inc	Biomarkers for predicting sensitivity to cancer treatments
TR201815685T4 (tr) *	2011-04-01	2018-11-21	Genentech Inc	Kanser tedavisi için akt ve mek inhibe edici bileşiklerin kombinasyonları.
CN104471070B (zh) *	2012-05-17	2018-09-25	基因泰克公司	制备羟基化环戊并嘧啶化合物和其盐的方法
KR102678074B1 (ko)	2012-05-17	2024-06-26	제넨테크, 인크.	무정형 형태의 akt 저해성 피리미디닐 - 사이클로펜탄 화합물, 조성물 및 이들의 방법
BR112014028589B1 (pt) *	2012-05-17	2022-08-23	Genentech, Inc.	Ciclopentilpirimidina hidroxilada, seu processo de fabricação e seus intermediários
MX2014013865A (es) *	2012-05-17	2015-05-07	Genentech Inc	Proceso para elaborar compuestos de ciclopentilpirimidina hidroxilada.
MA37751B1 (fr)	2012-05-17	2018-08-31	Genentech Inc	Procédé de préparation de composés d'acides aminés
US20150258127A1 (en)	2012-10-31	2015-09-17	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for preventing antiphospholipid syndrome (aps)
MX2015007054A (es) *	2012-12-07	2016-01-12	Gen Hospital Corp	Combinaciones de un compuesto inhibidor de pi3k/akt con un compuesto inhibidor de her3/egfr, y métodos de uso.
JP6340162B2 (ja)	2012-12-20	2018-06-06	日東電工株式会社	アポトーシス誘導剤
EP3068770B1 (fr) *	2013-11-15	2019-10-23	F.Hoffmann-La Roche Ag	Procédé de préparation de composés de pyrimidinylcyclopentane
MX368298B (es) *	2014-09-26	2019-09-27	Hoffmann La Roche	Procesos para preparar compuestos de (ciclopentil [d]pirimidin-4-il)piperazina.
CN116172869A (zh)	2016-08-10	2023-05-30	豪夫迈·罗氏有限公司	包含Akt蛋白激酶抑制剂的药物组合物
CA3041840A1 (fr)	2016-10-28	2018-05-03	Icahn School Of Medicine At Mount Sinai	Compositions et procedes pour le traitement du cancer a mediation par l'ezh2
US11472799B2 (en) *	2018-03-06	2022-10-18	Icahn School Of Medicine At Mount Sinai	Serine threonine kinase (AKT) degradation / disruption compounds and methods of use
CA3104298A1 (fr)	2018-06-21	2019-12-26	Icahn School Of Medicine At Mount Sinai	Composes de degradation/desintegration de la proteine 5 a domaine de repetition wd40 (wdr5) et methodes d'utilisation
WO2020131765A1 (fr)	2018-12-19	2020-06-25	Genentech, Inc.	Traitement du cancer du sein à l'aide de polythérapies comprenant un inhibiteur d'akt, un taxane et un inhibiteur de pd-l1
CN113195000A (zh)	2018-12-21	2021-07-30	第一三共株式会社	抗体-药物缀合物和激酶抑制剂的组合
KR102892239B1 (ko)	2019-01-29	2025-11-26	난징 치아 타이 티안큉 파마슈티컬 컴파니 리미티드	Akt 억제제
EP3946330A1 (fr)	2019-03-29	2022-02-09	Institut National de la Santé et de la Recherche Médicale (INSERM)	Méthodes de traitement de chéloïdes, de cicatrices hypertrophiques et/ou de troubles de l'hyperpigmentation
CA3134491A1 (fr) *	2019-04-09	2020-10-15	Dana-Farber Cancer Institute, Inc.	Degradation d'akt par la conjugaison de l'inhibiteur d'akt competitif de l'atp gdc-0068 avec des ligands de ligase e3 et procedes d'utilisation
CN114423463B (zh)	2019-05-06	2025-09-26	西奈山伊坎医学院	作为hpk1的降解剂的异双功能化合物
WO2021185238A1 (fr) *	2020-03-17	2021-09-23	江苏恒瑞医药股份有限公司	Dérivé bicyclique fusionné, son procédé de préparation et son utilisation pharmaceutique
US12103924B2 (en)	2020-06-01	2024-10-01	Icahn School Of Medicine At Mount Sinai	Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
MX2022015322A (es)	2020-06-16	2023-01-11	Hoffmann La Roche	Proceso para elaborar compuestos de ciclopentilpirimidina hidroxilada.
CN115836069B (zh)	2020-07-22	2024-02-06	南京正大天晴制药有限公司	一种二氢吡啶并[2,3-d]嘧啶酮衍生物的盐、其制备方法及用途
TWI750905B (zh) *	2020-11-19	2021-12-21	財團法人國家衛生研究院	噻唑化合物作為蛋白質激酶抑制劑
KR102689151B1 (ko) *	2021-09-06	2024-07-29	연세대학교 산학협력단	Akt 신호경로 억제제를 유효성분으로 포함하는 아토피피부염의 예방 또는 치료용 조성물
WO2023043869A1 (fr) *	2021-09-15	2023-03-23	Teva Pharmaceuticals International Gmbh	Formes à l'état solide de citrate d'ipatasertib
CN113788834B (zh) *	2021-09-18	2022-11-29	河南奥思恩医药科技有限公司	2,4-二氯-6,7-二氢-5H-吡咯并[3,4-d]嘧啶盐酸盐的制备方法
CN117677614A (zh) *	2021-12-17	2024-03-08	中国医药研究开发中心有限公司	具有akt激酶抑制活性的杂环化合物及其制备方法和医药用途
CA3255389A1 (fr)	2022-03-31	2023-10-05	Astrazeneca Ab	Inhibiteurs de tyrosine kinase du récepteur du facteur de croissance épidermique (egfr) en combinaison avec un inhibiteur d'akt pour le traitement du cancer
CN120051280A (zh)	2022-10-17	2025-05-27	阿斯利康(瑞典)有限公司	用于治疗癌症的serd的组合
JP2025539034A (ja)	2022-11-11	2025-12-03	アストラゼネカ・アクチエボラーグ	癌の治療のための併用療法
EP4658768A1 (fr)	2023-01-31	2025-12-10	F. Hoffmann-La Roche AG	Cétoréductase mutante à activité cétoréductase accrue ainsi que procédés et utilisations les concernant
EP4643858A1 (fr)	2024-04-29	2025-11-05	Institut National de la Santé et de la Recherche Médicale	Procédés et composition pharmaceutique pour le traitement d'une maladie utérine

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
NL7112938A (fr) *	1970-09-30	1972-04-05
US5543523A (en)	1994-11-15	1996-08-06	Regents Of The University Of Minnesota	Method and intermediates for the synthesis of korupensamines
EP0958285B1 (fr) *	1997-01-08	2004-01-07	F.Hoffmann-La Roche Ag	BENZO[e]ISOINDOLES ET BENZO[h]ISOQUINOLEINES TRICYCLIQUES
ES2152902B1 (es) *	1999-07-27	2001-08-16	Medichem Sa	Procedimiento de obtencion de venlafaxina
ATE402169T1 (de) *	2000-08-18	2008-08-15	Millennium Pharm Inc	Quinazolin-derivate als kinase inhibitoren
ATE346064T1 (de) *	2000-09-15	2006-12-15	Vertex Pharma	Pyrazolverbindungen als protein-kinasehemmer
BR0208593A (pt) *	2001-03-30	2006-02-21	King Pharmaceuticals Res & Dev	método para o tratamento de um mamìfero, composto, e, composição farmacêutica
CA2468266A1 (fr) *	2001-12-06	2003-06-19	Merck & Co., Inc.	Inhibiteurs mitotiques de la kinesine
JP4469179B2 (ja) *	2002-01-23	2010-05-26	バイエルファーマセチカルコーポレーション	Ｒｈｏキナーゼ阻害剤としてのピリミジン誘導体
TW200306819A (en) *	2002-01-25	2003-12-01	Vertex Pharma	Indazole compounds useful as protein kinase inhibitors
PH12012501891A1 (en)	2003-11-21	2013-09-02	Array Biopharma Inc	Akt protein kinase inhibitors
EP1751133B1 (fr) *	2004-04-28	2010-04-14	Vertex Pharmaceuticals Incorporated	Compositions utiles en tant qu'inhibiteurs de la rock et d'autres proteines kinases
WO2005113762A1 (fr)	2004-05-18	2005-12-01	Pfizer Products Inc.	Structure cristalline de proteine kinase b-$g(a) (akt-1) et utilisations correspondantes
US20090131474A1 (en) *	2005-03-03	2009-05-21	Martino Forino	Screening methods for protein kinase b inhibitors employing virtual docking approaches and compounds and compositions discovered thereby
NZ573979A (en) *	2006-07-06	2012-02-24	Array Biopharma Inc	Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
ATE532789T1 (de) *	2006-07-06	2011-11-15	Array Biopharma Inc	Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
UA95641C2 (xx) *	2006-07-06	2011-08-25	Эррей Биофарма Инк.	Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы

2007
- 2007-05-07 UA UAA200900764A patent/UA95641C2/ru unknown
- 2007-07-05 KR KR1020157010625A patent/KR20150051240A/ko not_active Ceased
- 2007-07-05 ES ES07799337T patent/ES2372774T3/es active Active
- 2007-07-05 BR BR122013028012A patent/BR122013028012B8/pt active IP Right Grant
- 2007-07-05 WO PCT/US2007/072885 patent/WO2008006040A1/fr not_active Ceased
- 2007-07-05 BR BR122013028005A patent/BR122013028005B8/pt active IP Right Grant
- 2007-07-05 SI SI200731699T patent/SI2402325T1/sl unknown
- 2007-07-05 CA CA2656622A patent/CA2656622C/fr active Active
- 2007-07-05 NZ NZ610633A patent/NZ610633A/en unknown
- 2007-07-05 IN IN2886KON2014 patent/IN2014KN02886A/en unknown
- 2007-07-05 CN CN2012101841274A patent/CN102816124A/zh active Pending
- 2007-07-05 CA CA2836316A patent/CA2836316A1/fr not_active Abandoned
- 2007-07-05 KR KR1020137031899A patent/KR101578877B1/ko active Active
- 2007-07-05 SG SG2013019468A patent/SG188905A1/en unknown
- 2007-07-05 NZ NZ597647A patent/NZ597647A/xx unknown
- 2007-07-05 BR BRPI0713923A patent/BRPI0713923B8/pt active IP Right Grant
- 2007-07-05 ES ES11166125.2T patent/ES2554252T3/es active Active
- 2007-07-05 EP EP11166125.2A patent/EP2402325B1/fr active Active
- 2007-07-05 MX MX2008016202A patent/MX2008016202A/es active IP Right Grant
- 2007-07-05 DK DK07799337.6T patent/DK2049501T3/da active
- 2007-07-05 HU HUE11166125A patent/HUE026237T2/en unknown
- 2007-07-05 AU AU2007269060A patent/AU2007269060B2/en active Active
- 2007-07-05 RS RS20110551A patent/RS52212B/sr unknown
- 2007-07-05 MX MX2019008117A patent/MX377920B/es unknown
- 2007-07-05 KR KR1020147017714A patent/KR20140093291A/ko not_active Ceased
- 2007-07-05 SI SI200730780T patent/SI2049501T1/sl unknown
- 2007-07-05 MX MX2015013326A patent/MX366319B/es unknown
- 2007-07-05 EP EP11166123.7A patent/EP2399909B1/fr active Active
- 2007-07-05 DK DK11166125.2T patent/DK2402325T3/en active
- 2007-07-05 SG SG2012063863A patent/SG184706A1/en unknown
- 2007-07-05 CN CN2007800330851A patent/CN101578273B/zh active Active
- 2007-07-05 KR KR1020127011042A patent/KR101495408B1/ko active Active
- 2007-07-05 PL PL11166125T patent/PL2402325T3/pl unknown
- 2007-07-05 JP JP2009518636A patent/JP5266216B2/ja active Active
- 2007-07-05 EP EP15178003.8A patent/EP2966065A3/fr not_active Withdrawn
- 2007-07-05 EP EP07799337A patent/EP2049501B1/fr active Active
- 2007-07-05 AT AT07799337T patent/ATE524447T1/de active
- 2007-07-05 KR KR1020097002395A patent/KR101178672B1/ko active Active
- 2007-07-05 MY MYPI20090024A patent/MY147364A/en unknown
- 2007-07-05 HR HR20110908T patent/HRP20110908T1/hr unknown
- 2007-07-05 PT PT07799337T patent/PT2049501E/pt unknown
- 2007-07-05 SG SG2012082871A patent/SG185980A1/en unknown
- 2007-07-05 NZ NZ573732A patent/NZ573732A/en unknown
- 2007-07-05 ES ES11166123.7T patent/ES2554228T3/es active Active
- 2007-07-05 RU RU2009103900/04A patent/RU2478632C2/ru active
- 2007-07-05 PL PL07799337T patent/PL2049501T3/pl unknown
- 2007-07-05 SG SG10201802127UA patent/SG10201802127UA/en unknown
- 2007-07-06 CL CL200701993A patent/CL2007001993A1/es unknown
- 2007-07-06 TW TW102117449A patent/TW201332994A/zh unknown
- 2007-07-06 AR ARP070103033A patent/AR061842A1/es not_active Application Discontinuation
- 2007-07-06 TW TW096124780A patent/TWI402266B/zh active
2008
- 2008-12-17 MX MX2011010569A patent/MX337843B/es unknown
- 2008-12-18 IL IL196028A patent/IL196028A/en active IP Right Grant
2009
- 2009-01-05 ZA ZA200900070A patent/ZA200900070B/xx unknown
- 2009-02-03 MA MA31609A patent/MA31655B1/fr unknown
- 2009-02-04 CO CO09010508A patent/CO6150161A2/es unknown
- 2009-02-05 CR CR10600A patent/CR10600A/es unknown
- 2009-02-05 NO NO20090581A patent/NO342346B1/no unknown
2011
- 2011-12-08 CY CY20111101222T patent/CY1112117T1/el unknown
2012
- 2012-12-20 RU RU2012155606/04A patent/RU2012155606A/ru not_active Application Discontinuation
2013
- 2013-02-19 JP JP2013029956A patent/JP5836294B2/ja active Active
- 2013-06-26 JP JP2013133983A patent/JP2013177470A/ja active Pending
- 2013-12-05 AR ARP130104510A patent/AR093810A2/es unknown
2014
- 2014-09-16 JP JP2014188238A patent/JP2014231530A/ja not_active Withdrawn
2015
- 2015-09-20 IL IL241705A patent/IL241705A0/en unknown
2017
- 2017-08-25 AR ARP170102366A patent/AR109424A2/es active IP Right Grant

Also Published As

Publication number	Publication date
BRPI0713923B1 (pt)	2020-09-29
AR109424A2 (es)	2018-11-28
CA2656622C (fr)	2017-09-12
MA31655B1 (fr)	2010-09-01
MX377920B (es)	2025-03-11
KR20150051240A (ko)	2015-05-11
EP2402325B1 (fr)	2015-08-26
EP2049501B1 (fr)	2011-09-14
AU2007269060A1 (en)	2008-01-10
BR122013028012B8 (pt)	2021-05-25
IL241705A0 (en)	2015-11-30
IL196028A (en)	2017-02-28
EP2399909B1 (fr)	2015-08-26
CA2656622A1 (fr)	2008-01-10
MX2008016202A (es)	2009-02-11
SG10201802127UA (en)	2018-04-27
NZ573732A (en)	2012-03-30
RU2478632C2 (ru)	2013-04-10
CN101578273B (zh)	2012-11-14
KR20090030333A (ko)	2009-03-24
ES2372774T3 (es)	2012-01-26
KR20140093291A (ko)	2014-07-25
AU2007269060B2 (en)	2014-02-20
JP2013091670A (ja)	2013-05-16
SG185980A1 (en)	2012-12-28
IN2014KN02886A (fr)	2015-05-08
JP2014231530A (ja)	2014-12-11
CA2836316A1 (fr)	2008-01-10
NZ610633A (en)	2014-12-24
RU2009103900A (ru)	2010-08-20
IL196028A0 (en)	2009-09-01
EP2966065A2 (fr)	2016-01-13
TWI402266B (zh)	2013-07-21
AR093810A2 (es)	2015-06-24
SG188905A1 (en)	2013-04-30
TW201332994A (zh)	2013-08-16
NO20090581L (no)	2009-04-06
CL2007001993A1 (es)	2008-06-20
BR122013028005B1 (pt)	2021-04-06
ATE524447T1 (de)	2011-09-15
WO2008006040A1 (fr)	2008-01-10
PL2049501T3 (pl)	2012-02-29
ES2554252T3 (es)	2015-12-17
TW200817373A (en)	2008-04-16
SG184706A1 (en)	2012-10-30
NZ597647A (en)	2013-08-30
HRP20110908T1 (hr)	2012-02-29
NO342346B1 (no)	2018-05-07
SI2402325T1 (sl)	2015-12-31
BR122013028012B1 (pt)	2021-04-06
AR061842A1 (es)	2008-09-24
ES2554228T3 (es)	2015-12-17
DK2049501T3 (da)	2011-12-12
KR20130029364A (ko)	2013-03-22
MX337843B (es)	2016-03-22
CN102816124A (zh)	2012-12-12
HK1160134A1 (en)	2012-08-10
CN101578273A (zh)	2009-11-11
RU2012155606A (ru)	2014-06-27
DK2402325T3 (en)	2015-12-07
EP2966065A3 (fr)	2016-03-02
EP2049501A1 (fr)	2009-04-22
RS52212B (sr)	2012-10-31
KR101495408B1 (ko)	2015-02-25
CR10600A (es)	2009-02-20
BR122013028005B8 (pt)	2021-05-25
HUE026237T2 (en)	2016-06-28
CO6150161A2 (es)	2010-04-20
HK1126768A1 (en)	2009-09-11
MX366319B (es)	2019-07-05
KR20130141717A (ko)	2013-12-26
JP2009542723A (ja)	2009-12-03
KR101178672B1 (ko)	2012-09-07
SI2049501T1 (sl)	2012-01-31
EP2402325A2 (fr)	2012-01-04
JP5266216B2 (ja)	2013-08-21
JP5836294B2 (ja)	2015-12-24
BRPI0713923B8 (pt)	2021-05-25
CY1112117T1 (el)	2015-11-04
EP2399909A1 (fr)	2011-12-28
JP2013177470A (ja)	2013-09-09
MX2019008117A (es)	2019-09-04
UA95641C2 (xx)	2011-08-25
BRPI0713923A2 (pt)	2013-07-02
PL2402325T3 (pl)	2016-01-29
KR101578877B1 (ko)	2016-02-22
PT2049501E (pt)	2011-12-30
MY147364A (en)	2012-11-30
EP2402325A3 (fr)	2012-06-13
HK1160638A1 (en)	2012-08-10

Publication	Publication Date	Title
IL241705A0 (en)	2015-11-30	Hydroxylated and methoxylated cyclopenta[d]pyrimidines as akt protein kinase inhibitors
IL196051A0 (en)	2009-09-01	Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
IL284889A (en)	2021-08-31	Imidazotriazines and imidazopyrimidines as kinase inhibitors
EP2114983B8 (fr)	2015-02-18	Inhibiteurs des recepteurs axl a activite tyrosine kinase et procedes de fabrication et d'utilisation de ceux-ci
AU2005310968A1 (en)	2006-06-08	Bicyclic amides as kinase inhibitors
IL195005A0 (en)	2009-08-03	Inhibitors of akt (protein kinase b)
IL206607A0 (en)	2010-12-30	Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
ZA200809545B (en)	2010-01-27	Inhibitors of Akt (protein kinase B)
HK1133434A (en)	2010-03-26	Axl tyrosine kinase inhibitors and methods of making and using the same
HK1090927A (en)	2007-01-05	Pyrazolotriazines as kinase inhibitors
HK1103087A (en)	2007-12-14	Imidazopyrazine as tyrosine kinase inhibitors
HK1136161A (en)	2010-06-25	Methods of identifying activators of lyn kinase
HK1127060A (en)	2009-09-18	Imidazopyrazines as protein kinase inhibitors
HK1122021A (en)	2009-05-08	Imidazopyrazines as protein kinase inhibitors
HK1127030A (en)	2009-09-18	2-carbocycloamino-4-imidazolylpyrimidines as agents for the inhbition of cell proliferation
HK1126497A (en)	2009-09-04	Inhibitors of akt (protein kinase b)
HK1139147A (en)	2010-09-10	Imidazopyrazines as protein kinase inhibitors
HK1134814A (en)	2010-05-14	Benzofuropyrimidinones as protein kinase inhibitors